Refractory Acute Myeloid Leukemia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Refractory Acute Myeloid Leukemia – Pipeline Review, H2 2016’, provides an overview of the Refractory Acute Myeloid Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Refractory Acute Myeloid Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Acute Myeloid Leukemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia

The report reviews pipeline therapeutics for Refractory Acute Myeloid Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Refractory Acute Myeloid Leukemia therapeutics and enlists all their major and minor projects

The report assesses Refractory Acute Myeloid Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Refractory Acute Myeloid Leukemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Actinium Pharmaceuticals Inc

ADC Therapeutics Sarl

Aeglea BioTherapeutics Inc

Agios Pharmaceuticals Inc

Aileron Therapeutics Inc

Amgen Inc

Arog Pharmaceuticals Inc

Array BioPharma Inc

Astellas Pharma Inc

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Bellicum Pharmaceuticals Inc

Bio-Cancer Treatment International Ltd

BioLineRx Ltd

BioSight Ltd

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calithera Biosciences Inc

Celgene Corp

Cornerstone Pharmaceuticals Inc

CSPC Pharmaceutical Group Limited

CTI BioPharma Corp

Daiichi Sankyo Company Ltd

Eisai Co Ltd

Eli Lilly and Company

EpiZyme Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

FLX Bio, Inc.

FORMA Therapeutics Inc

Fujifilm Corp

GlaxoSmithKline Plc

GlycoMimetics Inc

Igenica Biotherapeutics Inc

Incyte Corp

Io Therapeutics Inc

JW Pharmaceutical Corp

Karyopharm Therapeutics Inc

Kyowa Hakko Kirin Co Ltd

MacroGenics Inc

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

NantKwest Inc

Novartis AG

Oxford BioTherapeutics Ltd

Pfizer Inc

Pharma Mar SA

Polaris Pharmaceuticals Inc

Seattle Genetics Inc

Sunesis Pharmaceuticals Inc

TaiGen Biotechnology Co Ltd

Tolero Pharmaceuticals Inc

Tragara Pharmaceuticals Inc

VioQuest Pharmaceuticals Inc

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Refractory Acute Myeloid Leukemia Overview 7

Therapeutics Development 8

Refractory Acute Myeloid Leukemia - Therapeutics under Development by Companies 10

Refractory Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes 14

Refractory Acute Myeloid Leukemia - Pipeline Products Glance 15

Refractory Acute Myeloid Leukemia - Products under Development by Companies 18

Refractory Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes 24

Refractory Acute Myeloid Leukemia - Companies Involved in Therapeutics Development 25

Refractory Acute Myeloid Leukemia - Therapeutics Assessment 85

Drug Profiles 107

Refractory Acute Myeloid Leukemia - Dormant Projects 448

Refractory Acute Myeloid Leukemia - Discontinued Products 451

Refractory Acute Myeloid Leukemia - Product Development Milestones 452

Appendix 465

List of Tables

List of Tables

Number of Products under Development for Refractory Acute Myeloid Leukemia, H2 2016 19

Number of Products under Development for Refractory Acute Myeloid Leukemia – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Development by Companies, H2 2016 (Contd..1) 22

Number of Products under Development by Companies, H2 2016 (Contd..2) 23

Number of Products under Development by Companies, H2 2016 (Contd..3) 24

Number of Products under Investigation by Universities/Institutes, H2 2016 25

Comparative Analysis by Late Stage Development, H2 2016 26

Comparative Analysis by Clinical Stage Development, H2 2016 27

Comparative Analysis by Early Stage Development, H2 2016 28

Products under Development by Companies, H2 2016 29

Products under Development by Companies, H2 2016 (Contd..1) 30

Products under Development by Companies, H2 2016 (Contd..2) 31

Products under Development by Companies, H2 2016 (Contd..3) 32

Products under Development by Companies, H2 2016 (Contd..4) 33

Products under Development by Companies, H2 2016 (Contd..5) 34

Products under Investigation by Universities/Institutes, H2 2016 35

Refractory Acute Myeloid Leukemia – Pipeline by 4SC AG, H2 2016 36

Refractory Acute Myeloid Leukemia – Pipeline by AbbVie Inc, H2 2016 37

Refractory Acute Myeloid Leukemia – Pipeline by Actinium Pharmaceuticals Inc, H2 2016 38

Refractory Acute Myeloid Leukemia – Pipeline by ADC Therapeutics Sarl, H2 2016 39

Refractory Acute Myeloid Leukemia – Pipeline by Aeglea BioTherapeutics Inc, H2 2016 40

Refractory Acute Myeloid Leukemia – Pipeline by Agios Pharmaceuticals Inc, H2 2016 41

Refractory Acute Myeloid Leukemia – Pipeline by Aileron Therapeutics Inc, H2 2016 42

Refractory Acute Myeloid Leukemia – Pipeline by Amgen Inc, H2 2016 43

Refractory Acute Myeloid Leukemia – Pipeline by Arog Pharmaceuticals Inc, H2 2016 44

Refractory Acute Myeloid Leukemia – Pipeline by Array BioPharma Inc, H2 2016 45

Refractory Acute Myeloid Leukemia – Pipeline by Astellas Pharma Inc, H2 2016 46

Refractory Acute Myeloid Leukemia – Pipeline by AstraZeneca Plc, H2 2016 47

Refractory Acute Myeloid Leukemia – Pipeline by AVEO Pharmaceuticals Inc, H2 2016 48

Refractory Acute Myeloid Leukemia – Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 49

Refractory Acute Myeloid Leukemia – Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 50

Refractory Acute Myeloid Leukemia – Pipeline by BioLineRx Ltd, H2 2016 51

Refractory Acute Myeloid Leukemia – Pipeline by BioSight Ltd, H2 2016 52

Refractory Acute Myeloid Leukemia – Pipeline by Boehringer Ingelheim GmbH, H2 2016 53

Refractory Acute Myeloid Leukemia – Pipeline by Boston Biomedical Inc, H2 2016 54

Refractory Acute Myeloid Leukemia – Pipeline by Bristol-Myers Squibb Company, H2 2016 55

Refractory Acute Myeloid Leukemia – Pipeline by Calithera Biosciences Inc, H2 2016 56

Refractory Acute Myeloid Leukemia – Pipeline by Celgene Corp, H2 2016 57

Refractory Acute Myeloid Leukemia – Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 58

Refractory Acute Myeloid Leukemia – Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 59

Refractory Acute Myeloid Leukemia – Pipeline by CTI BioPharma Corp, H2 2016 60

Refractory Acute Myeloid Leukemia – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 61

Refractory Acute Myeloid Leukemia – Pipeline by Eisai Co Ltd, H2 2016 62

Refractory Acute Myeloid Leukemia – Pipeline by Eli Lilly and Company, H2 2016 63

Refractory Acute Myeloid Leukemia – Pipeline by EpiZyme Inc, H2 2016 64

Refractory Acute Myeloid Leukemia – Pipeline by Exelixis Inc, H2 2016 65

Refractory Acute Myeloid Leukemia – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 66

Refractory Acute Myeloid Leukemia – Pipeline by Fate Therapeutics Inc, H2 2016 67

Refractory Acute Myeloid Leukemia – Pipeline by FLX Bio, Inc., H2 2016 68

Refractory Acute Myeloid Leukemia – Pipeline by FORMA Therapeutics Inc, H2 2016 69

Refractory Acute Myeloid Leukemia – Pipeline by Fujifilm Corp, H2 2016 70

Refractory Acute Myeloid Leukemia – Pipeline by GlaxoSmithKline Plc, H2 2016 71

Refractory Acute Myeloid Leukemia – Pipeline by GlycoMimetics Inc, H2 2016 72

Refractory Acute Myeloid Leukemia – Pipeline by Igenica Biotherapeutics Inc, H2 2016 73

Refractory Acute Myeloid Leukemia – Pipeline by Incyte Corp, H2 2016 74

Refractory Acute Myeloid Leukemia – Pipeline by Io Therapeutics Inc, H2 2016 75

Refractory Acute Myeloid Leukemia – Pipeline by JW Pharmaceutical Corp, H2 2016 76

Refractory Acute Myeloid Leukemia – Pipeline by Karyopharm Therapeutics Inc, H2 2016 77

Refractory Acute Myeloid Leukemia – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 78

Refractory Acute Myeloid Leukemia – Pipeline by MacroGenics Inc, H2 2016 79

Refractory Acute Myeloid Leukemia – Pipeline by Merck & Co Inc, H2 2016 80

Refractory Acute Myeloid Leukemia – Pipeline by Merck KGaA, H2 2016 81

Refractory Acute Myeloid Leukemia – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 82

Refractory Acute Myeloid Leukemia – Pipeline by NantKwest Inc, H2 2016 83

Refractory Acute Myeloid Leukemia – Pipeline by Novartis AG, H2 2016 84

Refractory Acute Myeloid Leukemia – Pipeline by Oxford BioTherapeutics Ltd, H2 2016 85

Refractory Acute Myeloid Leukemia – Pipeline by Pfizer Inc, H2 2016 86

Refractory Acute Myeloid Leukemia – Pipeline by Pharma Mar SA, H2 2016 87

Refractory Acute Myeloid Leukemia – Pipeline by Polaris Pharmaceuticals Inc, H2 2016 88

Refractory Acute Myeloid Leukemia – Pipeline by Seattle Genetics Inc, H2 2016 89

Refractory Acute Myeloid Leukemia – Pipeline by Sunesis Pharmaceuticals Inc, H2 2016 90

Refractory Acute Myeloid Leukemia – Pipeline by TaiGen Biotechnology Co Ltd, H2 2016 91

Refractory Acute Myeloid Leukemia – Pipeline by Tolero Pharmaceuticals Inc, H2 2016 92

Refractory Acute Myeloid Leukemia – Pipeline by Tragara Pharmaceuticals Inc, H2 2016 93

Refractory Acute Myeloid Leukemia – Pipeline by VioQuest Pharmaceuticals Inc, H2 2016 94

Refractory Acute Myeloid Leukemia – Pipeline by ZIOPHARM Oncology Inc, H2 2016 95

Assessment by Monotherapy Products, H2 2016 96

Assessment by Combination Products, H2 2016 97

Number of Products by Stage and Target, H2 2016 99

Number of Products by Stage and Mechanism of Action, H2 2016 107

Number of Products by Stage and Route of Administration, H2 2016 115

Number of Products by Stage and Molecule Type, H2 2016 117

Refractory Acute Myeloid Leukemia – Dormant Projects, H2 2016 459

Refractory Acute Myeloid Leukemia – Dormant Projects (Contd..1), H2 2016 460

Refractory Acute Myeloid Leukemia – Dormant Projects (Contd..2), H2 2016 461

Refractory Acute Myeloid Leukemia – Discontinued Products, H2 2016 462

List of Figures

List of Figures

Number of Products under Development for Refractory Acute Myeloid Leukemia, H2 2016 19

Number of Products under Development for Refractory Acute Myeloid Leukemia – Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Investigation by Universities/Institutes, H2 2016 25

Comparative Analysis by Late Stage Development, H2 2016 26

Comparative Analysis by Clinical Stage Development, H2 2016 27

Comparative Analysis by Early Stage Products, H2 2016 28

Assessment by Monotherapy Products, H2 2016 96

Number of Products by Top 10 Targets, H2 2016 98

Number of Products by Stage and Top 10 Targets, H2 2016 98

Number of Products by Top 10 Mechanism of Actions, H2 2016 106

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 106

Number of Products by Routes of Administration, H2 2016 114

Number of Products by Stage and Routes of Administration, H2 2016 114

Number of Products by Molecule Types, H2 2016 116

Number of Products by Stage and Molecule Types, H2 2016 116

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports